Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Biotechnology
A draft issued on March 29 by China’s National Health Commission (CNHC), which regulates hospitals in China, allows qualified 3 Jia ( meaning top-level) public hospitals to develop and commercialize somatic cell therapies within their own hospitals. 17 May 2019
Pharmaceutical
Lithuania's new assessment procedure for reimbursable medicines: will there be any positive changes?
Lithuanian attorney Ruta Pumputiene provides an Expert View on amendments to the Lithuanian Pharmaceutical Law and the subsequent changes to the reimbursable medicines system. 15 May 2019
Generics
Shares of Indian pharmaceutical companies continued their downward slide on reports that a lawsuit has been filed against Teva Pharmaceuticals Industries and other generic companies in the USA, including many Indian drugmakers, by 44 US states. 15 May 2019
Pharmaceutical
Japan pharma market data and company results for FY2018 (ending March 2019) are becoming available, and they paint a beautiful picture for some and best-to-forget message for others, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 13 May 2019
Pharmaceutical
Learning from the standards set by the USA, Europe and Brazil, Colombia is fast catching up in making the country an attractive place to research, seek approval for and market medicines, according to Yaneth Giha Tovar, executive president of AFRIDO, the national trade association for the pharmaceutical industry. 13 May 2019
Pharmaceutical
Global drugmakers operating in Russia are unhappy with the current quality of clinical trials organized in Russia on the basis of local centers, according to recent statements of some representatives of the companies, reports The Pharma Letter’s local correspondent. 13 May 2019
Pharmaceutical
The existing sanctions regime against Russia may lead to the shortage of drugs in the local market over the next several years, according to recent statements by analysts of the Russian Ministry of Health and some local experts in the field of pharmaceuticals, reports The Pharma Letter’s local correspondent. 13 May 2019
Pharmaceutical
In 2018, the FDA set a new record in the number of new drug approvals, with a total of 59 new drugs approved by its Center for Drug Evaluation and Research (CDER).1 So far in 2019, the CDER has approved 8 drugs, with 6 of these approvals happening in the first quarter of the year,2 exactly the same number that was approved in the first quarter of 2018.3 10 May 2019
Pharmaceutical
In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker. 10 May 2019
Pharmaceutical
Edward Jones, policy and communications consultant at GK Strategy, provides an Expert View on how companies can take advantage of the UK National Health Service's policy initiatives to support market access and uptake. 10 May 2019
Pharmaceutical
An Expert View column on how a valuable patent protection encourages development and helps to fund future battles provided by Robert Watson, partner, and Sarah Kostiuk-Smith, European patent attorney, from Mewburn Ellis. 8 May 2019
Biosimilars
Swiss pharma giant Roche’s non-Hodgkin’s lymphoma treatment MabThera (rituximab) is facing a strong rival in China - its biosimilar version Hanlikang from Fosun Pharma’s biotech arm Henlius. 7 May 2019
Generics
Leading Russian drugmaker Biocad plans to commission its new large-scale production facility in the St Petersburg Neudorf special economic zone next month, with the aim to significantly increase its domestic production capacities. according to the company, reports The Pharma Letter’s local correspondent. 7 May 2019
Pharmaceutical
Top Russian pharmaceutical manufacturers and global drugmakers, operating in the local market have called on the government to provide additional guarantees for the safety of their business in the country and to create conditions for their comfortable development in the local market. 7 May 2019
Biotechnology
Thankfully, the growing anti-microbial resistance (AMR) crisis is now getting some major headlines and airtime, so that even many lay people are getting a good grasp of the issues at the heart of this global priority. 2 May 2019
Generics
The issuing of a compulsory license for the production of a patent-protected drug in Russia may take place shortly, due to the recent victory of several legal disputes with US pharma giant Pfizer by local drugmaker Nativa, reports The Pharma Letter’s local correspondent. 30 April 2019
Pharmaceutical
ViiV Healthcare has officially launched full-cycle production of an innovative drug for the treatment of HIV in Russia at the facilities of French independent drugmaker Servier’s plant in Moscow. 30 April 2019
Pharmaceutical
The fight against malaria received a shot in the arm with a range of research organizations bonding together on a common platform in a bid to eliminate the disease from India by 2030 through shared research agenda and resources, reports The Pharma Letter’s India correspondent. 29 April 2019
Pharmaceutical
In an Expert View piece, Oliver Kidd, senior associate at Stevens & Bolton, provides an overview of an ever-more complex landscape. 24 April 2019
Biotechnology
Russia’s Research Institute of Highly Pure Biopreparations, a St Petersburg-based producer of active ingredients and drugs, plans to invest up to $20 million in the launch of production of certain drugs against anemia, as well as some active ingredients, with the aim of their further exports, according to the company, reports The Pharma Letter’s local correspondent. 24 April 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze